33 related articles for article (PubMed ID: 2405068)
1. Antiviral Strategies Using Natural Source-Derived Sulfated Polysaccharides in the Light of the COVID-19 Pandemic and Major Human Pathogenic Viruses.
Ray B; Ali I; Jana S; Mukherjee S; Pal S; Ray S; Schütz M; Marschall M
Viruses; 2021 Dec; 14(1):. PubMed ID: 35062238
[TBL] [Abstract][Full Text] [Related]
2. Macromolecular Antiviral Agents against Zika, Ebola, SARS, and Other Pathogenic Viruses.
Schandock F; Riber CF; Röcker A; Müller JA; Harms M; Gajda P; Zuwala K; Andersen AHF; Løvschall KB; Tolstrup M; Kreppel F; Münch J; Zelikin AN
Adv Healthc Mater; 2017 Dec; 6(23):. PubMed ID: 28945945
[TBL] [Abstract][Full Text] [Related]
3. Long-acting slow effective release antiretroviral therapy.
Edagwa B; McMillan J; Sillman B; Gendelman HE
Expert Opin Drug Deliv; 2017 Nov; 14(11):1281-1291. PubMed ID: 28128004
[TBL] [Abstract][Full Text] [Related]
4. The protective effect of fucoidan in rats with streptozotocin-induced diabetic nephropathy.
Wang J; Liu H; Li N; Zhang Q; Zhang H
Mar Drugs; 2014 May; 12(6):3292-306. PubMed ID: 24886867
[TBL] [Abstract][Full Text] [Related]
5. Early inhibitors of human cytomegalovirus: state-of-art and therapeutic perspectives.
Mercorelli B; Lembo D; Palù G; Loregian A
Pharmacol Ther; 2011 Sep; 131(3):309-29. PubMed ID: 21570424
[TBL] [Abstract][Full Text] [Related]
6. Heparin inhibits IFN-gamma-induced fractalkine/CX3CL1 expression in human endothelial cells.
Hatakeyama M; Imaizumi T; Tamo W; Yamashita K; Yoshida H; Fukuda I; Satoh K
Inflammation; 2004 Feb; 28(1):7-13. PubMed ID: 15072225
[TBL] [Abstract][Full Text] [Related]
7. Structure-function relations of heparin-mimetic sulfated xylan oligosaccharides: inhibition of human immunodeficiency virus-1 infectivity in vitro.
Stone AL; Melton DJ; Lewis MS
Glycoconj J; 1998 Jul; 15(7):697-712. PubMed ID: 9881776
[TBL] [Abstract][Full Text] [Related]
8. Identification of a CD36-related thrombospondin 1-binding domain in HIV-1 envelope glycoprotein gp120: relationship to HIV-1-specific inhibitory factors in human saliva.
Crombie R; Silverstein RL; MacLow C; Pearce SF; Nachman RL; Laurence J
J Exp Med; 1998 Jan; 187(1):25-35. PubMed ID: 9419208
[TBL] [Abstract][Full Text] [Related]
9. Infection by HIV-1 blocked by binding of dextrin 2-sulphate to the cell surface of activated human peripheral blood mononuclear cells and cultured T-cells.
Shaunak S; Gooderham NJ; Edwards RJ; Payvandi N; Javan CM; Baggett N; MacDermot J; Weber JN; Davies DS
Br J Pharmacol; 1994 Sep; 113(1):151-8. PubMed ID: 7812605
[TBL] [Abstract][Full Text] [Related]
10. Antiviral therapy for human immunodeficiency virus infections.
De Clercq E
Clin Microbiol Rev; 1995 Apr; 8(2):200-39. PubMed ID: 7542558
[TBL] [Abstract][Full Text] [Related]
11. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions.
Callahan LN; Phelan M; Mallinson M; Norcross MA
J Virol; 1991 Mar; 65(3):1543-50. PubMed ID: 1995952
[TBL] [Abstract][Full Text] [Related]
12. Sulfated polyanions do not inhibit duck hepatitis B virus infection.
Offensperger WB; Offensperger S; Walter E; Blum HE; Gerok W
Antimicrob Agents Chemother; 1991 Nov; 35(11):2431-3. PubMed ID: 1804020
[TBL] [Abstract][Full Text] [Related]
13. Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus.
Andrei G; Snoeck R; Schols D; Goubau P; Desmyter J; De Clercq E
Eur J Clin Microbiol Infect Dis; 1991 Dec; 10(12):1026-33. PubMed ID: 1666361
[TBL] [Abstract][Full Text] [Related]
14. Anti-AIDS drug development: challenges and strategies.
Mohan P
Pharm Res; 1992 Jun; 9(6):703-14. PubMed ID: 1384026
[TBL] [Abstract][Full Text] [Related]
15. Comparative activity of various compounds against clinical strains of herpes simplex virus.
Andrei G; Snoeck R; Goubau P; Desmyter J; De Clercq E
Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):143-51. PubMed ID: 1327785
[TBL] [Abstract][Full Text] [Related]
16. Novel sulfated polysaccharides: dissociation of anti-human immunodeficiency virus activity from antithrombin activity.
Baba M; De Clercq E; Schols D; Pauwels R; Snoeck R; Van Boeckel C; Van Dedem G; Kraaijeveld N; Hobbelen P; Ottenheijm H
J Infect Dis; 1990 Feb; 161(2):208-13. PubMed ID: 2405068
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro.
Baba M; Pauwels R; Balzarini J; Arnout J; Desmyter J; De Clercq E
Proc Natl Acad Sci U S A; 1988 Aug; 85(16):6132-6. PubMed ID: 2457906
[TBL] [Abstract][Full Text] [Related]
18. Novel sulfated polymers as highly potent and selective inhibitors of human immunodeficiency virus replication and giant cell formation.
Baba M; Schols D; De Clercq E; Pauwels R; Nagy M; Györgyi-Edelényi J; Löw M; Görög S
Antimicrob Agents Chemother; 1990 Jan; 34(1):134-8. PubMed ID: 2327749
[TBL] [Abstract][Full Text] [Related]
19. Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro.
Baba M; Nakajima M; Schols D; Pauwels R; Balzarini J; De Clercq E
Antiviral Res; 1988 Sep; 9(6):335-43. PubMed ID: 2465736
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
